monozygotic (MZ) twins with a 22ql deletion who were discordant for cardiac defects. I have recently met a similar family where all the affected members have had a 22ql deletion detected by FISH.
Twin 1 has a typical facial appearance of the velocardiofacial syndrome (figure) with nasal speech but no cardiac defect detectable clinically or on ECG. Twin 2 required a pharyngoplasty for nasopharyngeal insufficiency and had surgery for an ASD during childhood. She has a very similar facies and both had mild learning difficulties during childhood.
Facial appearance of twin 1.
Twin 1 has a daughter with mild learning difficulties and similar appearance with a normal heart (on clinical and ECG examination) but twin 2 had an affected daughter who died following surgery for Fallot's tetralogy with absent pulmonary valve and hemitruncus. In addition, this child's heart showed severe pulmonary regurgitation and peripheral pulmonary artery stenosis and the left pulmonary artery took its origin from a branch of the aorta. Twin 2 has subsequently had another child with a 22qll deletion but a normal heart on echocardiography.
DNA studies using six microsatellite polymorphisms on six different chromosomes gives a probability of greater than 99% that the twins are monozygous. They compare their data with a similar follow up study comparing CTG expansion sizes in muscle2 in which the authors observed no progression in the size of the CTG length in repeated muscle biopsies from three adult DM patients. According to Martorell et al,' one possible explanation for this finding would be a negative selection in muscle above a maximum size limit. In this case continued CTG expansions would be seen only in relatively young DM patients.
We have compared the size of the CTG expansion in muscle and lymphocytes in 19 DM patients of different ages (including three children) and varying clinical severity and our data support such a hypothesis.
In accordance with previous publications23 we have found that the size of the expansion was always greater in muscle than in blood, with no correlation in adults with age at onset or severity of the phenotype.4 However, surprisingly, the smallest difference between the size of the expansion in muscle and the size of the expansion in lymphocytes was observed in the affected children (two with congenital DM and in one 11 year old patient with onset in early childhood). In these three young patients, this difference ranged from 2.1 kb to 4.2kb while in adult patients it ranged from 5.3 kb to 9.0 kb. A significant correlation (s9=0.64, p<0.05) was found between patients' age and the difference in the expansion between muscle and lymphocytes.
In summary, although we have not analysed repeated biopsies from the same person (owing to the difficulty of obtaining such samples), we would like to point out that our data suggest that the size of the CTG repeat in muscle increases with age in young DM affected patients, apparently reaching a plateau in adulthood. Moreover, in young DM cases, it seems that the progression in the size of the CTG expansion in muscle may be greater than that observed in peripheral blood. The practice of withholding testing from applicants is clearly at odds with the psychotherapeutic model of genetic counselling, as discussed by Sharpe2: "the geneticist must explicitly acknowledge that at all times decision making remains under the control of the patient; that the geneticist must act in accordance with a patient's decisions irrespective of how the geneticist may perceive their rationality or competence". It also contradicts the notion ofproviding information in response to the counselee's specific questions: an applicant for predictive testing who is suspected to be symptomatic may want to know whether (s)he carries the gene for HD, rather than whether (s)he is currently affected.
There are clearly occasions when the clinician's concern to "do no harm" is perceived * It is unclear whether these requests came from clinicians or individual people.
